Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(100.0%)
1Total
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04166487Phase 2Active Not Recruiting

Plasma-Adapted First-Line Pembro In NSCLC

Role: collaborator

NCT05116618Withdrawn

Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged

Role: collaborator

NCT03116633Completed

Concordance of Inivata Liquid Biopsy With Standard Tissue Biopsy

Role: lead

NCT02906852Completed

Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing

Role: lead

All 4 trials loaded